Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy
| Autor: | Matthias Schwenkglenks, Antonio Lopez Pousa, Gary H. Lyman, S. Lawrinson, Matti Aapro, T. Skacel, P. Bacon, Gunter von Minckwitz |
|---|---|
| Přispěvatelé: | University of Zurich, Aapro, M |
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
Neutropenia Filgrastim 2720 Hematology Febrile neutropenia Population 610 Medicine & health Antineoplastic Agents Breast Neoplasms Primary prophylaxis G-CSF Polyethylene Glycols Breast cancer Elderly Internal medicine Granulocyte Colony-Stimulating Factor medicine Humans Chemotherapy education Aged education.field_of_study Leukopenia business.industry Incidence (epidemiology) 10060 Epidemiology Biostatistics and Prevention Institute (EBPI) Hematology medicine.disease Recombinant Proteins Pegfilgrastim Surgery Oncology 2730 Oncology Female medicine.symptom business medicine.drug |
| Zdroj: | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname |
| ISSN: | 1040-8428 |
| DOI: | 10.1016/j.critrevonc.2009.06.004 |
| Popis: | We investigated the incidences of febrile neutropenia (FN) and related complications in elderly (>= 65 years) breast cancer patients receiving chemotherapy supported by pegfilgrastim primary prophylaxis (PP; n=150) or current practice (CP) neutropenia management (n=104) in a subanalysis of NeuCuP (Neulasta (R) vs. current practice neutropenia management). Studies involving regimens with moderately high to high (>= 15%) FN risk were identified by literature review, and individual patient data were integrated for analysis. FN incidence was 6% (95% CI: 2, 10%) in the PP group and 24% (95% CI: 16, 32%) in the CP group. In cycle 1, incidences were 3 and 15%, respectively. FN-related hospitalisation incidence was 5% (PP group) and 15% (CP group), while dose reductions (>= 15%) occurred in 15 and 29% of patients. Pegfilgrastim provided effective PP in elderly patients, a population who may be vulnerable to chemotherapy-related FN and for whom current practice may not provide adequate protection. (C) 2009 Published by Elsevier Ireland Ltd. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect